ライフサイエンスコーパス: leukotriene B4

1 were not mirrored by other eicosanoids (i.e. leukotriene B4).

2 sion molecule 1, P-selectin, L-selectin, and leukotriene B4.

3 ary membrane protein permeability, IL-8, and leukotriene B4.

4 IL-8, IL-6, tumor necrosis factor-alpha, and leukotriene B4.

5 tion during sepsis and increased circulating leukotriene B4.

6 ed [Ca2+]i, while it inhibited the action of leukotriene B4.

7 pocytes, and is mediated by the secretion of leukotriene B4.

8 the amniotic cavity reveals up-regulation of leukotriene B4.

9 ntly reduced without affecting the levels of leukotriene B4.

10 idase without affecting the bioproduction of leukotriene B4.

11 llular signaling that leads to production of leukotriene B4.

12 in a relative narrow concentration range for leukotriene B4 (100-200 nm).

13 cosatetraenoic acid, cysteinyl leukotrienes, leukotriene B4 , 11-dehydro-thromboxane B2 , and prostag

14 Rat NADP-dependent leukotriene B4 12-hydroxydehydrogenase (Ltb4dh) catalyze

15 eductase (AO), an enzyme heretofore known as leukotriene B4 12-hydroxydehydrogenase, 15-oxoprostaglan

16 ion of leukotriene B4, (LTB4) and 20-hydroxy-leukotriene B4 (20-OH-LTB4).

17 tors (LM) via metabololipidomics, CO reduced leukotriene B4 (21 +/- 11 versus 59 +/- 24 pg/mouse, 6 h

18 oid metabolites 5-oxo-eicosatetraenoic acid, leukotriene B4 5-hydroxyeicosatetraenoic acid (HETE), 12

19 aT, significantly inhibited the formation of leukotriene B4, a potent chemotactic agent synthesized b

20 CYP4F3A inactivates leukotriene B4, a reaction that has significance for con

21 that BLT2, a G protein-coupled receptor for leukotriene B4 and 12(S)-hydroxyheptadecatrienoic acid (

22 products, MDA, gamma-glutamyl peptides, GGT, leukotriene B4 and 5-HETE.

23 acisoga and variants in LPP, and derivative leukotriene B4 and intergenic variants in chr10p14.

24 Leukotriene B4 and interleukin-8, known chemoattractants

25 Recently, leukotriene B4 and its high affinity receptor, BLT1, hav

26 sor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small mol

27 ntegrins, in concert with neutrophil-derived leukotriene B4 and other chemoattractants, promote local

28 spect to inflammatory lipid mediators (i.e., leukotriene B4 and PGs) in omental adipose tissue from O

29 ediators including prostaglandin F2alpha and leukotriene B4 and pro-resolving mediators, including re

30 ectious exudates gave higher proinflammatory leukotriene B4 and procoagulating thromboxane B2, as wel

31 e included inflammation initiating mediators leukotriene B4 and prostaglandin E2 and pro-resolving me

32 vels of the pro-inflammatory lipid mediators leukotriene B4 and prostaglandin E2 are elevated in the

33 l infiltration and prevented the increase in leukotriene B4 and prostaglandin E2 in response to ische

34 Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated wi

35 n expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant d

36 ase n-6 PUFA-derived lipid mediators such as leukotriene B4 and prostaglandin E2.

37 ities of cell-associated AA mimicked that of leukotriene B4 and PtdCho/PtdIns, while the specific act

38 howing a decrease in BALF levels of IL-8 and leukotriene B4 and the associated reduction of BALF neut

39 onophore (A23187), and the concentrations of leukotrienes B4 and B5, thromboxane A2, prostaglandin E2

40 mbers correlated with the enhanced levels of leukotrienes B4 and C4 and prostaglandin E2 produced aft

41 pha; prostaglandins E1, D2, and F2 alpha and leukotrienes B4 and C4 were detected in lower amounts.

42 secrete the inflammatory eicosanoid products leukotrienes B4 and C4, the cytokines IL-6 and TNF, and

43 ane A2 analog U-46619; AngaD7L2 weakly binds leukotrienes B4 and D4; and AngaD7L3 binds serotonin.

44 on between rs174537 and the ratio of ARA/LA, leukotriene B4, and 5-HETE but no effect on levels of cy

45 ils exposed to chemoattractants (IL-8, FMLP, leukotriene B4, and C5a) failed to show increases in int

46 EIA determined leukotriene B4, and ELISAs quantified TNF, IL-12 and IL-

47 ositol hexakisphosphate, lipopolysaccharide, leukotriene B4, and granulocyte-macrophage colony-stimul

48 h the chemoattractants N-formyl-Met-Leu-Phe, leukotriene B4, and interleukin-8 exhibits threshold beh

49 tion of soluble factors including adenosine, leukotriene B4, and several chemokines.

50 f synthesis of the potent chemotactic factor leukotriene B4, and that process was reversed by rottler

51 ylated peptides, platelet-activating factor, leukotriene B4, and the complement anaphylatoxins.

52 Despite this, leukotriene B4 antagonism with acebilustat did not short

53 phonuclear leukocyte infiltration induced by leukotriene B4 (approximately 78% inhibition) or phorbol

54 ages and identify Plg-mediated regulation of leukotriene B4 as an underlying mechanism.

55 To determine the opsonin dependence of the leukotriene B4 augmentation of phagocytosis, we assessed

56 While leukotriene B4 augmented both Fc receptor- and complemen

57 Ratios of thromboxane B2,/B3, leukotriene B4/B5, and prostaglandin E2/E1 were reduced

58 -lipoxygenase-deficient mice, the absence of leukotriene B4 biosynthesis did not detectably alter m-B

59 oup V phospholipase A2 (hVPLA2) could elicit leukotriene B4 biosynthesis in human neutrophils through

60 nd of the thiazole series, by inhibiting the leukotriene B4 biosynthesis in the RPAR assay (3 h pretr

61 show that PGE2-G, but not PGE2-EA, inhibits leukotriene B4 biosynthesis, superoxide production, migr

62 RvE1 binds to leukotriene B4 (BLT-1) on neutrophils and to ERV-1/ChemR

63 B4/mg protein, p < .001) generation of ileal leukotriene B4, but did not alter the cyclooxygenase pro

64 N-formyl-methionyl-leucyl-phenylalanine and leukotriene B4, by approximately 65%, but had no effect

65 ctive on the same responses when elicited by leukotriene B4, C5a, FMLP, platelet-activating factor, I

66 The neutrophil count and leukotriene B4 concentration in bronchoalveolar lavage f

67 Importantly, higher leukotriene B4 concentrations (>0.5 mum) and BLT2 agonis

68 Leukotriene B4 decreased in 4-aminopyridine and EPI grou

69 migration of PMN toward the chemoattractant leukotriene B4, decreased uptake of L. monocytogenes by

70 plication of this method to the synthesis of leukotriene B4 demonstrates its utility and extraordinar

71 s, i.e. platelet activating factor (PAF) and leukotriene B4, did not inhibit the responses of peptide

72 In contrast, AACOCF3 potently inhibited leukotriene B4 formation by ionophore-stimulated neutrop

73 s from various mammalian cells and to elicit leukotriene B4 formation from human neutrophils.

74 the release of high mobility group box 1 and leukotriene B4 from the epithelial cells and this releas

75 ociated with significant reductions in ileal leukotriene B4 generation and neutrophilic infiltrate.

76 Two major G-protein-coupled receptors for leukotriene B4 have been identified: the high-affinity r

77 oncentration in exhaled breath condensate of leukotriene B4, hydrogen peroxide and hydrogen ions rose

78 .05), but there was no significant change in leukotriene B4, hydrogen peroxide, or hydrogen ion conce

79 P4F regulators in vitro, effecting increased leukotriene B4 hydroxylation (inactivation).

80 ive prostaglandin E2 (iPGE2), immunoreactive leukotriene B4 (iLTB4), and pain after periodontal surge

81 d in decreased levels of prostaglandin E2 or leukotriene B4 in intestinal polyps or apparently normal

82 ic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4 in particular could serve as potential bi

83 clusion, we have identified a novel role for leukotriene B4 in the augmentation of neutrophil phagocy

84 In the antiprostacyclin antibody group, leukotriene B4 increased immediately after starting anti

85 Accordingly, leukotriene B4-induced thermal hyperalgesia was mediated

86 study, we explored the effect of the C5 and leukotriene B4 inhibitor Ornithodoros moubata complement

87 Acebilustat, a leukotriene B4 inhibitor, has potential to reduce inflam

88 dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pemphigoid disorders, and c

89 -Leu-Phe (fMLP), platelet-activating factor, leukotriene B4, interleukin-8, or the chemokine RANTES e

90 Leukotriene B4 is a lipid mediator that recently has bee

91 Leukotriene B4 is a proinflammatory lipid mediator whose

92 The levels of leukotriene B4, leukotriene C4/D4, 6-keto-prostaglandin

93 ly increase bronchoalveolar lavage levels of leukotriene B4, leukotriene C4/D4, and thromboxane B2 ab

94 ronchoalveolar lavage fluid was analyzed for leukotriene B4, leukotriene C4/D4, thromboxane B2, prost

95 inflammatory responses mediated through the leukotriene B4/leukotriene B4 receptor type 1 (BLT1) sig

96 mplement complex and significantly decreased leukotriene B4 levels in septic pigs.

97 displaced by 5-oxoETE analogues, but not by leukotriene B4, lipoxin A4, or lipoxin B4.

98 e (fMLP)), platelet activating factor (PAF), leukotriene B4 (LTB(4)), C5a anaphylotoxin (C5a), and in

99 -) eosinophils and neutrophils had decreased leukotriene B4 (LTB(4))-dependent chemotactic responses

100 zyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB(4)).

101 ly hypertensive rat (SHR) support a role for leukotriene B4 (LTB4 ), a potent chemoattractant involve

102 ly hypertensive rat (SHR) support a role for leukotriene B4 (LTB4 ), a potent chemoattractant involve

103 lbumin (65.6 versus 53.0 micrograms/ml), and leukotriene B4 (LTB4) (243 versus 0 pg/ml) in BAL fluid

104 Leukotriene B4 (LTB4) activates the G-protein-coupled re

105 Prolonged exposure of PMN to leukotriene B4 (LTB4) afforded dose-dependent inhibition

106 ease in the abundance of the proinflammatory leukotriene B4 (LTB4) and a corresponding decrease in th

107 r the conversion of leukotriene A4 (LTA4) to leukotriene B4 (LTB4) and also possesses an aminopeptida

108 nition systems for other chemotaxins such as leukotriene B4 (LTB4) and fMLP is unknown.

109 mediated by signaling through the chemokine leukotriene B4 (LTB4) and its receptor LTB4R1.

110 Eicosanoids, such as leukotriene B4 (LTB4) and lipoxin A4 (LXA4), may play a

111 on and secretion of interleukin 8 (IL-8) and leukotriene B4 (LTB4) and was prevented by mitochondrial

112 ediators such as prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are implicated in the development

113 mediated) biosynthesis of the lipid mediator leukotriene B4 (LTB4) are pivotal components of host def

114 Important roles for tyrosine kinase Syk and leukotriene B4 (LTB4) are recognized in FcgammaR-mediate

115 i-MCP-1 Abs reduced the peritoneal levels of leukotriene B4 (LTB4) by 59%.

116 x was largely dependent on the generation of leukotriene B4 (LTB4) by neutrophils and their expressio

117 Leukotriene B4 (LTB4) contributes to many inflammatory d

118 The synthetic 13S,14S-epoxide inhibited leukotriene B4 (LTB4) formation by human leukotriene A4

119 igration toward increasing concentrations of leukotriene B4 (LTB4) in a chemotaxis assay in vitro, wh

120 ygenase (5LO) and its chemotactic metabolite leukotriene B4 (LTB4) in KSHV biology.

121 23 activates the synthesis and production of leukotriene B4 (LTB4) in myeloid cells, which modulate i

122 ion has demonstrated the mechanistic role of leukotriene B4 (LTB4) in the molecular pathogenesis of l

123 YBB-) neutrophils produced higher amounts of leukotriene B4 (LTB4) in vitro after activation with zym

124 Leukotriene B4 (LTB4) is a chemotactic and cell-activati

125 Leukotriene B4 (LTB4) is a major proinflammatory mediato

126 Leukotriene B4 (LTB4) is a potent activator and chemoatt

127 Leukotriene B4 (LTB4) is a potent chemoattractant for my

128 Leukotriene B4 (LTB4) is a potent chemoattractant for ne

129 Leukotriene B4 (LTB4) is a rapidly synthesized, early le

130 The pro-inflammatory mediator leukotriene B4 (LTB4) is implicated in the pathologies o

131 of airway hyperresponsiveness (AHR) and that leukotriene B4 (LTB4) is involved in the chemotaxis of e

132 Leukotriene B4 (LTB4) is secreted by chemotactic neutrop

133 codynamic (PD) relationship based on ex vivo leukotriene B4 (LTB4) levels in dog.

134 We measured lipoxin A4 (LXA4) and leukotriene B4 (LTB4) levels in EBC collected from patie

135 ith palmitate, enhanced arginase 1 and lower leukotriene B4 (LTB4) levels were detected in macrophage

136 udy was designed to test the hypothesis that leukotriene B4 (LTB4) may have a role in graft rejection

137 We tested the hypothesis that leukotriene B4 (LTB4) mediates the effects of toxin A vi

138 (approximately 80% reduction) in response to leukotriene B4 (LTB4) plus prostaglandin E2 (PGE2) as we

139 5-lipoxygenase (5-LO) activity and increased leukotriene B4 (LTB4) production have been implicated in

140 rease exudate volume, cell infiltration, and leukotriene B4 (LTB4) production in response to zymosan

141 n reported to be a purinoceptor (P2Y7) and a leukotriene B4 (LTB4) receptor (BLTR).

142 99mTc-RP517 is a new leukotriene B4 (LTB4) receptor antagonist developed for

143 ctivity study based around the high-affinity leukotriene B4 (LTB4) receptor antagonist SB 201146 (1)

144 The first potent leukotriene B4 (LTB4) receptor type 2 (BLT2) agonists, e

145 ugh 5'-lipoxygenase or via antagonism of the leukotriene B4 (LTB4) receptor.

146 ted as antagonists of the human cell surface leukotriene B4 (LTB4) receptor.

147 rrow-derived DCs (BM-DCs) express functional leukotriene B4 (LTB4) receptors as observed in dose-depe

148 It has been reported that leukotriene B4 (LTB4) reduces the parasitic load of infe

149 The eicosanoid leukotriene B4 (LTB4) relays chemotactic signals to dire

150 e lymphotoxin-stimulated neovasculature with leukotriene B4 (LTB4) resulted in stable cell adhesion f

151 Mucosal synthesis of the chemoattractant leukotriene B4 (LTB4) significantly increased after I-R

152 Leukotriene B4 (LTB4) stimulates neutrophils to adhere l

153 hat nuclear positioning plays in determining leukotriene B4 (LTB4) synthesis.

154 In human neutrophils, leukotriene B4 (LTB4) triggered rapid decreases in PSDP

155 e or mice treated with an ACEI produced less leukotriene B4 (LTB4) upon stimulation with MRSA or lipo

156 e demonstrate that the lipid chemoattractant leukotriene B4 (LTB4) was efficacious at causing loss of

157 In 36 preparations, concentration of leukotriene B4 (LTB4) was measured in treated tracheal p

158 Leukotriene B4 (LTB4) was more potent than cysteinyl LTs

159 Leukotriene B4 (LTB4) was originally described as a pote

160 )-mediated C5 activation and also sequesters leukotriene B4 (LTB4) within an internal binding pocket.

161 g by autocoids with opposing actions on PMN: leukotriene B4 (LTB4), a potent chemoattractant, and lip

162 The cellular origin of leukotriene B4 (LTB4), a potent pro-inflammatory molecul

163 They are the main source of leukotriene B4 (LTB4), a potent proinflammatory lipid me

164 Leukotriene B4 (LTB4), a product of the lipoxygenase pat

165 Leukotriene B4 (LTB4), a proinflammatory mediator produc

166 B4(LXB4) blocked PMN migration stimulated by leukotriene B4 (LTB4), a well established agonist for PM

167 glandin E2 (PGE2) and 5-LO-derived products, leukotriene B4 (LTB4), and the biosynthesis interaction

168 s known that 5-lipoxygenase and its product, leukotriene B4 (LTB4), are highly expressed in several h

169 ), and the ratio of SPMs to pro-inflammatory leukotriene B4 (LTB4), are significantly decreased in th

170 as hydroxyeicosatetraenoic acids (HETEs) and leukotriene B4 (LTB4), can be converted by cells in cult

171 on of leukotrienes, and more specifically on leukotriene B4 (LTB4), for disease induction as well as

172 ), LXA4, and its counterregulatory compound, leukotriene B4 (LTB4), in patients with childhood asthma

173 (TxB2), prostaglandin 6-keto-F1alpha (PGI), leukotriene B4 (LTB4), leukotriene C4D4E4 (LTC4D4E4), in

174 Rat alveolar macrophages produced leukotriene B4 (LTB4), LTC4, and 5-hydoxyeicosatetraenoi

175 than C5a, platelet-activating factor (PAF), leukotriene B4 (LTB4), or FMLP in stimulating Eo chemota

176 onditions and after administration of either leukotriene B4 (LTB4), platelet-activating factor (PAF),

177 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and inte

178 X favors the biosynthesis of proinflammatory leukotriene B4 (LTB4), whereas, in theory, cytoplasmic 5

179 ion of inflammatory mediators, TNF-alpha and leukotriene B4 (LTB4), which are involved in parasite ki

180 eukotoxin (LKT) stimulates the production of leukotriene B4 (LTB4), which is believed to be an import

181 Here, leukotriene B4 (LTB4)-induced PMN influx in ear skin was

182 blocks platelet activating factor (PAF)- and leukotriene B4 (LTB4)-induced responses.

183 l memory, CD8+ T cells through production of leukotriene B4 (LTB4).

184 o platelet-activating factor (PAF), C5a, and leukotriene B4 (LTB4).

185 SF), and the eiconsanoids thromboxane A2 and leukotriene B4 (LTB4).

186 tifs, synthetic origins, and bioactions with leukotriene B4 (LTB4).

187 l-leucyl-phenylalanine (fMLP) is mediated by leukotriene B4 (LTB4).

188 eutrophil production of a second eicosanoid, leukotriene B4 (LTB4).

189 d mediating general neutrophil chemotaxis is leukotriene B4 (LTB4).

190 MLP signal over a competing chemoattractant, leukotriene B4 (LTB4).

191 enrichment of the chemotactic gradient with leukotriene B4 (LTB4).

192 ted a high affinity and specific binding for leukotriene B4 (LTB4, Kd = 0.24 +/- 0.03 nM).

193 s, synthetic N-acetyl-PGP, positive control (leukotriene B4 [LTB4]), or negative control (Hanks' bala

194 g (most notably of the inflammatory mediator leukotriene B4 [LTB4]).

195 ided exogenously) inhibited the formation of leukotriene B4, (LTB4) and 20-hydroxy-leukotriene B4 (20

196 Leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotri

197 ulated (16.0 +/- 4.9 vs. 80.0 +/- 15.5 pg of leukotriene B4/mg protein, p < .001) generation of ileal

198 th basal (8.0 +/- 1.9 vs. 33.0 +/- 8.1 pg of leukotriene B4/mg protein, p < .05) and ionophore-stimul

199 animals did not produce prostaglandin E2 or leukotriene B4 or C4.

200 dent manner (P < 0.05) but did not attenuate leukotriene B4 or complement-activated serum ECA.

201 Inhibition of leukotriene B4 or integrin rescues maturation and migrat

202 cytes to ATLa but not to the chemoattractant leukotriene B4 or vehicle alone.

203 after stimulation of either neutrophils (by leukotriene B4) or coronary endothelium (by thrombin) in

204 HETE), or lipoxygenase metabolites (5S-HETE, leukotriene B4, or lipoxin A4).

205 Tenascin did not affect leukotriene B4- or fMLP-stimulated expression of beta1 o

206 into perspective with the data obtained with leukotriene B4, our results illuminate the ligand select

207 Phospholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-LOX/LTB4) axis is an important in

208 duced 5-[3H]oxoETE binding, whereas 15-HETE, leukotriene B4, platelet-activating factor, IL-8, C5a, a

209 ved an increase in neutrophil chemotaxis and leukotriene B4 production and increased expression of ac

210 s may involve local intestinal inhibition of leukotriene B4 production and subsequent neutrophilic in

211 of neutrophilic infiltrate, an inhibition of leukotriene B4 production, and a facilitation of mucosal

212 cant decrease in IgE-mediated degranulation, leukotriene B4 production, cytokine secretion, and survi

213 pofol binds to 5-lipoxygenase and attenuates leukotriene B4 production.

214 Concentrations of leukotriene B4, prostaglandin E2, and thromboxane B2 rel

215 Plasma levels of histamine, leukotriene B4, prostaglandin E2, prostaglandin F2, pH,

216 The mouse leukotriene B4 receptor (m-BLTR) gene was cloned.

217 e also identified neuroprotectin D1 as a new leukotriene B4 receptor 1 (BLT(1)) agonist, implying an

218 The leukotriene B4 receptor 1 (BLT1) regulates the recruitme

219 B4) activates the G-protein-coupled receptor leukotriene B4 receptor 1 (BLT1) to mediate a diverse ar

220 that signals via its cell surface receptor, leukotriene B4 receptor 1 (BLT1), to attract and activat

221 Although leukotriene B4 receptor 2 (BLT2) has been characterized

222 The leukotriene B4 receptor 2 (BLT2) is a G-protein coupled

223 The leukotriene B4 receptor 2 (BLT2) is a G-protein coupled

224 t 12-S-HHT, but not 16:4(n-3), functions via leukotriene B4 receptor 2 (BLT2).

225 Tumor suppression is associated with reduced leukotriene B4 receptor 2 (LTB4R2) and its high affinity

226 A leukotriene B4 receptor antagonist, ONO 4057, did not si

227 nstrate a unique, non-redundant role for the leukotriene B4 receptor BLT1 in mediating neutrophil rec

228 strategy was applied to a typical GPCR, the leukotriene B4 receptor BLT2, reconstituted in a lipid b

229 erved in human neutrophils pretreated with a leukotriene B4 receptor but not a cysteinyl-leukotriene

230 this study, we investigated the roles of the leukotriene B4 receptor, BLT1, and CXCR3, the receptor f

231 splicing were further investigated with the leukotriene B4 receptor, known for its aberrant responsi

232 e lung tumour burden and genetic deletion of leukotriene B4 receptor-1 (BLT1(-/-)) attenuates this in

233 le nitric oxide synthase, and antagonists of leukotriene B4 receptor.

234 Thus, the data show that the two leukotriene B4 receptors have opposing roles in the sens

235 mmunohistochemical analysis showed that both leukotriene B4 receptors were expressed in peripheral se

236 While leukotriene B4 reconstituted defective phagocytosis in l

237 osatetraenoic acid produced by platelets and leukotriene B4 released from calcium ionophore-activated

238 Leukotriene B4 rescued the suppression of CD36 expressio

239 of this defect, as it leads to activation of leukotriene B4 signaling and induction of the alpha4beta

240 covers a previously undefined role of innate leukotriene B4 signaling as a gatekeeper of the hematopo

241 ve migration toward worms requires paracrine leukotriene B4 signaling between eosinophils.

242 hors show that changing miRNA biogenesis and leukotriene B4 signaling in mice modulates this switch i

243 Inactivation of leukotriene B4 signaling or genetic deficiency of PPARal

244 of collagen I or Matrigel, and chemotaxis of leukotriene B4-stimulated PMN through fibrin gels.

245 cosanoids--e.g., 12(R)-HETE, 12(S)-HETE, and leukotriene B4--stimulated the activation of NF-kappaB r

246 We found that leukotriene B4 stimulates neutrophil deployment.

247 LF levels of total protein, neutrophils, and leukotriene B4 tended to decrease in EPA+GLA patients ov

248 L)-8, IL-6, tumor necrosis factor-alpha, and leukotriene B4 that are responsible, in part, for pulmon

249 ammatory arachidonic acid-derived mediators, leukotriene B4, thromboxane B2, and prostaglandin E2 fro

250 ctions in the generation of pro-inflammatory leukotriene B4, thus LTA4H exhibits opposing pro- and an

251 olites of the 5-lipoxygenase pathway such as leukotriene B4 to activate the peroxisome proliferator-a

252 of phagocytosis, we assessed the ability of leukotriene B4 to modulate neutrophil phagocytosis and t

253 MCs release the attractant leukotriene B4 to re-route neutrophils toward them, thus

254 ediated phagocytosis, increased adherence to leukotriene B4-treated neutrophils was limited to comple

255 ic acid, 5-hydroxyeicosatetraenoic acid, and leukotriene B4), TRPV4 (5,6-epoxyeicosatrienoic acid [EE

256 spectively) but generated greater amounts of leukotriene B4 upon maximal stimulation (26.6 versus 7.6

257 enylalanine, platelet activating factor, and leukotriene B4 was phosphoinositide-3 kinase-dependent,

258 potent neutrophil activator/chemoattractant leukotriene B4 were measured by mass spectrometry in ski

259 The eicosanoid mediators, thromboxane and leukotriene B4, were also highest in the severe asthma g

260 ntrations of leukotrienes C4, D4, and E4 and leukotriene B4, whereas prostacyclin infusion suppressed

261 elay among neutrophils mediated by the lipid leukotriene B4, which acutely amplifies local cell death

262 the production of the inflammatory mediator leukotriene B4, which is involved in inflammatory respon

263 ne, 5-hydroperoxy eicosatetraenoic acid, and leukotriene B4, which show potential to be further inves